Filtros de búsqueda

Lista de obras de John M. Maris

11q deletion in neuroblastoma: a review of biological and clinical implications.

artículo científico publicado en 2017

131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.

artículo científico publicado en 2015

A 6-gene signature identifies four molecular subgroups of neuroblastoma

artículo científico publicado en 2011

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

artículo científico publicado en 2018

A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope

artículo científico publicado en 2021

A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.

artículo científico

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma

artículo científico publicado en 2016

A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity

artículo científico publicado en 2020

A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity

artículo científico publicado en 2020

A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Children's Oncology Group

artículo científico publicado en 2016

A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene

artículo científico publicado en 2008

A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.

artículo científico publicado en 2006

A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors

artículo científico publicado en 2008

A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1

artículo científico publicado en 2013

A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study

artículo científico publicado en 2012

A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3

artículo científico publicado en 1995

A three-gene expression signature model for risk stratification of patients with neuroblastoma

artículo científico publicado en 2012

ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry

scientific article published on 09 December 2019

ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation.

artículo científico publicado en 2012

ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures

scientific article published on 17 October 2019

Abstract B75: Defining the antitumor activity and sensitivity profiles of BET inhibitors in neuroblastoma

artículo científico publicado en 2014

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

scientific article published on 09 July 2020

Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature

artículo científico publicado en 2010

Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia

artículo científico publicado en 2004

Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms

artículo científico publicado en 2008

Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations

artículo científico publicado en 2015

Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group

artículo científico publicado en 2014

Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas

article

Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma

article

An integrated transcript map of human chromosome 1p35-p36.

artículo científico publicado en 1997

Analysis of genomic imprinting at 1p35-36 in neuroblastoma

artículo científico publicado en 2001

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

artículo científico publicado en 2010

Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study

artículo científico publicado en 2019

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study

artículo científico publicado en 2010

Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues

artículo científico publicado en 2017

Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study ⬇️

artículo científico publicado en 2017

Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism.

artículo científico publicado en 2015

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study

artículo científico publicado en 2015

BIN1 inhibits colony formation and induces apoptosis in neuroblastoma cell lines with MYCN amplification

scientific article published on 01 December 2000

Biodistribution of post-therapeutic versus diagnostic (131)I-MIBG scans in children with neuroblastoma

artículo científico publicado en 2004

Biological aspects of neuroblastomas identified by mass screening in Quebec

artículo científico publicado en 2001

Biology and genetics of human neuroblastomas.

artículo científico publicado en 1997

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

artículo científico publicado en 2018

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma

artículo científico publicado en 2020

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

scientific article published on 17 January 2019

CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus

artículo científico publicado en 2015

CGHAnalyzer: a stand-alone software package for cancer genome analysis using array-based DNA copy number data

artículo científico publicado en 2005

CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas

artículo científico publicado en 2008

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.

artículo científico publicado en 2012

Chemotherapy for neuroblastoma: is it all or none?

artículo científico publicado en 2003

Children's Oncology Group's 2013 blueprint for research: neuroblastoma

artículo científico

Chromosome 1p and 11q deletions and outcome in neuroblastoma

artículo científico publicado en 2005

Chromosome 6p22 locus associated with clinically aggressive neuroblastoma

artículo científico publicado en 2008

Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro

artículo científico publicado en 2010

Clinical utility of custom-designed NGS panel testing in pediatric tumors

Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma

artículo científico publicado en 2018

Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.

artículo científico publicado en 2009

Clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction

Cloning, chromosomal localization, physical mapping, and genomic characterization of HKR3

artículo científico publicado en 1996

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.

artículo científico publicado en 2011

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.

artículo científico publicado en 2011

Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.

artículo científico publicado en 2012

Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha

artículo científico publicado en 2010

Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition

artículo científico publicado en 2019

Common genetic variants in NEFL influence gene expression and neuroblastoma risk

artículo científico publicado en 2014

Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

artículo científico publicado en 2017

Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma

scientific journal article

Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity

artículo científico publicado en 2012

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

artículo científico publicado en 2009

Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma

artículo científico publicado en 2009

Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis.

artículo científico publicado en 2009

Comprehensive Analysis of Hypermutation in Human Cancer

artículo científico publicado en 2017

Comprehensive analysis of chromosome 1p deletions in neuroblastoma

article

Congenital neuroblastoma arising in the deltoid muscle

scientific article published on 01 February 2004

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

artículo científico publicado en 2015

Copy number variation at 1q21.1 associated with neuroblastoma

artículo científico publicado en 2009

Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma

artículo científico publicado en 2017

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931

scientific article published on 16 July 2018

Corrigendum: Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines

artículo científico publicado en 2017

Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.

artículo científico publicado en 2018

Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs

artículo científico publicado en 2021

Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531

artículo científico publicado en 2018

Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma

artículo científico publicado en 2005

Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas

artículo científico publicado en 2000

Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification

artículo científico publicado en 2007

Detailed molecular analysis of 1p36 in neuroblastoma

article

Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction

artículo científico publicado en 2003

Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations

artículo científico publicado en 2016

Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma

artículo científico publicado en 2019

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

artículo científico publicado en 2011

Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes

artículo científico publicado en 2016

Does MYCN Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study

artículo científico publicado en 2006

Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial

artículo científico publicado en 2012

Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers

artículo científico publicado en 2021

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma

artículo científico publicado en 2013

ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.

artículo científico publicado en 2013

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial

artículo científico publicado en 2019

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

artículo científico publicado en 2011

Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.

artículo científico publicado en 2016

Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target

artículo científico publicado en 2021

Epigenomic profiling of neuroblastoma cell lines

scientific article published on 14 April 2020

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

artículo científico publicado en 2016

Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma

artículo científico publicado en 2017

Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group

artículo científico publicado en 2012

Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.

artículo científico publicado en 2006

Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13.

artículo científico publicado en 2002

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

article

Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart Disease

scientific article published on 30 August 2019

Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.

artículo científico publicado en 2003

Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease

artículo científico publicado en 1997

Familial neuroblastoma: report of a kindred with later age at diagnosis.

artículo científico publicado en 1998

Familial predisposition to neuroblastoma does not map to chromosome band 1p36

artículo científico publicado en 1996

Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study

artículo científico publicado en 2005

Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor

scientific article published on 04 October 2018

G-CSF Is a Cancer Stem Cell–Specific Growth Factor—Letter

artículo científico publicado en 2015

GENE-05. ATRX IN-FRAME FUSION NEUROBLASTOMA IS SENSITIVE TO EZH2 INHIBITION VIA MODULATION OF NEURONAL GENE SIGNATURES

artículo científico publicado en 2019

Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism.

artículo científico publicado en 2015

Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays

artículo científico publicado en 2007

Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma

artículo científico publicado en 2011

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

artículo científico publicado en 2018

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

scientific article published on 01 November 2019

Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra

artículo científico publicado en 2017

Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy.

artículo científico publicado en 2009

Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy.

artículo científico publicado en 2009

Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

artículo científico publicado en 2022

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

artículo científico publicado en 2010

Germline PHOX2B mutation in hereditary neuroblastoma

artículo científico publicado en 2004

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy

artículo científico publicado en 2017

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma

artículo científico publicado en 2004

Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastoma

artículo científico publicado en 2008

High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma

artículo científico publicado en 2006

High-resolution detection and mapping of genomic DNA alterations in neuroblastoma

artículo científico publicado en 2005

Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma

artículo científico publicado en 2001

Human Krüppel-related 3 (HKR3): a candidate for the 1p36 neuroblastoma tumour suppressor gene?

artículo científico publicado en 1997

Hyperdiploidy Plus NonamplifiedMYCNConfers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study

article

ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.

artículo científico publicado en 2003

IMMU-04. DEVELOPMENT OF GPC2-DIRECTED CHIMERIC ANTIGEN RECEPTOR THERAPY FOR PEDIATRIC BRAIN TUMORS WITH IN VITRO TRANSCRIBED mRNA

Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma

artículo científico publicado en 2003

Identification of ALK as a major familial neuroblastoma predisposition gene

artículo científico publicado en 2008

Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.

artículo científico publicado en 2017

Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity

artículo científico publicado en 2020

Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas

artículo científico publicado en 2000

Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity

artículo científico publicado en 1998

Identifying rare events in rare diseases

artículo científico publicado en 2014

Imaging genomics in cancer research: limitations and promises

scientific article published on 11 February 2016

Immunogenicity and Immune Silence in Human Cancer

scientific article published on 06 March 2020

Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma

artículo científico publicado en 2006

Immunotherapy for pediatric brain tumors: past and present

artículo científico publicado en 2019

Improving Patient Outcomes With Cancer Genomics: Unique Opportunities and Challenges in Pediatric Oncology

artículo científico publicado en 2015

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.

artículo científico publicado en 2016

Inhibition of ALK signaling for cancer therapy

artículo científico publicado en 2009

Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470.

artículo científico publicado en 2000

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2016

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

artículo científico publicado en 2015

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

artículo científico publicado en 2014

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

artículo científico publicado en 2011

Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2013

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

artículo científico publicado en 2013

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

artículo científico publicado en 2011

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2010

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

artículo científico publicado en 2014

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

artículo científico publicado en 2011

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

artículo científico publicado en 2011

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

artículo científico publicado en 2008

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

artículo científico publicado en 2013

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

artículo científico publicado en 2013

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

artículo científico publicado en 2009

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

scientific article published on February 2010

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

artículo científico publicado en 2008

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

artículo científico publicado en 2013

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

artículo científico publicado en 2010

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

artículo científico publicado en 2008

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

artículo científico publicado en 2010

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

artículo científico publicado en 2014

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2013

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.

artículo científico publicado en 2015

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

artículo científico publicado en 2016

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

artículo científico publicado en 2012

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

artículo científico publicado en 2013

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

artículo científico publicado en 2014

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

scientific article published on December 2009

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

artículo científico publicado en 2008

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

artículo científico publicado en 2011

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

artículo científico publicado en 2010

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

artículo científico publicado en 2014

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

artículo científico publicado en 2012

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

artículo científico publicado en 2011

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

artículo científico publicado en 2008

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).

artículo científico publicado en 2015

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

scientific article published on September 2009

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

artículo científico publicado en 2011

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2016

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2010

Initial testing of aplidin by the pediatric pre-clinical testing program.

artículo científico publicado en 2009

Initial testing of cisplatin by the pediatric preclinical testing program

artículo científico publicado en 2008

Initial testing of dasatinib by the pediatric preclinical testing program

artículo científico publicado en 2008

Initial testing of lenalidomide by the pediatric preclinical testing program

artículo científico publicado en 2011

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

artículo científico publicado en 2011

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

artículo científico publicado en 2012

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

artículo científico publicado en 2008

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

artículo científico publicado en 2010

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

artículo científico publicado en 2010

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

scientific article published on 19 October 2011

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

artículo científico publicado en 2010

Initial testing of topotecan by the pediatric preclinical testing program.

artículo científico publicado en 2010

Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients

artículo científico publicado en 2014

Integrative genomics identifies LMO1 as a neuroblastoma oncogene

artículo científico publicado en 2010

Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number

artículo científico publicado en 2006

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee

artículo científico publicado en 2009

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial

Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study

scientific article published on 26 January 2009

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group

scientific article published on 28 April 2020

Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

artículo científico publicado en 2017

LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase

artículo científico publicado en 2020

LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis

artículo científico publicado en 2017

Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma

artículo científico publicado en 2010

Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma

scientific article published on 19 April 2020

Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13

artículo científico publicado en 2000

Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma

scientific article published on 27 April 2020

Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study

article

Loss of heterozygosity for chromosome 14q in neuroblastoma

artículo científico publicado en 2001

MBRS-57. TARGETING METABOLIC ADAPTATION IN MYC/MYCN AMPLIFIED PEDIATRIC MEDULLOBLASTOMA AND NEUROBLASTOMA

MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

artículo científico publicado en 2017

MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells.

artículo científico publicado en 2015

MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group

artículo científico publicado en 2017

MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation

artículo científico publicado en 2017

MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma

artículo científico publicado en 2015

Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531

artículo científico publicado en 2019

Malignant pheochromocytoma: current status and initiatives for future progress

artículo científico publicado en 2004

Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era.

artículo científico publicado en 2005

Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models

artículo científico publicado en 2005

Mitochondrial DNA haplogroups and susceptibility to neuroblastoma

artículo científico publicado en 2020

Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition

artículo científico publicado en 2012

Molecular analysis of the region of distal 1p commonly deleted in neuroblastoma.

artículo científico publicado en 1997

Molecular biology of neuroblastoma

artículo científico publicado en 1999

Molecular characterization of the pediatric preclinical testing panel

artículo científico publicado en 2008

Molecular genetic analysis of familial neuroblastoma

scientific article published on 01 October 1997

Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition

publication published on 09 February 2021

Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status.

artículo científico publicado en 2008

Neuroblastoma

artículo científico publicado en 2007

Neuroblastoma

artículo científico publicado en 2016

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

artículo científico publicado en 2017

Neuroblastoma in relation to joint effects of vitamin A and maternal and offspring variants in vitamin A-related genes: A report of the Children's Oncology Group

artículo científico publicado en 2019

Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group

artículo científico publicado en 2013

Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression

artículo científico publicado en 2007

New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome

artículo científico publicado en 2012

No CDKN2 mutations in neuroblastomas.

artículo científico publicado en 1995

No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3.

artículo científico publicado en 2002

Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization ⬇️

artículo científico publicado el 1 de julio de 1997

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma

artículo científico publicado en 2010

Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.

artículo científico publicado en 2012

Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group

artículo científico publicado en 2009

Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma

scientific article published on 07 February 2019

PARP-1-targeted Auger emitters display high-LET cytotoxic properties in vitro but show limited therapeutic utility in solid tumor models of human neuroblastoma

artículo científico publicado en 2019

PDTM-02. STRESS GRANULES ARE INDUCED BY OXIDATIVE STRESS IN PEDIATRIC BRAIN TUMORS AND PREDICT POOR OUTCOME

artículo científico publicado en 2018

PDTM-46. TARGETING METABOLIC ADAPTATION IN MYC DRIVEN PEDIATRIC NEURONAL TUMORS

artículo científico publicado en 2017

PI3King on MYCN to improve neuroblastoma therapeutics

artículo científico publicado en 2012

PRIMA-1-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.

artículo científico publicado en 2018

Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations

scientific article published on 14 October 2020

Pediatric horner syndrome

artículo científico publicado en 2011

Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions

artículo científico publicado en 2006

Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study

artículo científico publicado en 2012

Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee

artículo científico publicado en 2012

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

artículo científico publicado en 2015

Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors.

artículo científico publicado en 2010

Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.

artículo científico publicado en 2014

Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)

scientific article published on 19 December 2019

Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

artículo científico publicado en 2012

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

artículo científico publicado en 2016

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

artículo científico publicado en 2006

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

artículo científico publicado en 2013

Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study ⬇️

artículo científico publicado el 22 de febrero de 2011

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study

artículo científico publicado en 2009

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

artículo científico publicado en 2018

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study

artículo científico publicado en 2010

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

artículo científico publicado en 2007

Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci.

artículo científico publicado en 2011

Physical mapping and genomic structure of the human TNFR2 gene

artículo científico publicado en 1996

Physical mapping of the CA6, ENO1, and SLC2A5 (GLUT5) genes and reassignment of SLC2A5 to 1p36.2

artículo científico publicado en 1998

Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.

artículo científico publicado en 2015

Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma

artículo científico publicado en 2003

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

artículo científico publicado en 2016

Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma ⬇️

artículo científico publicado el 12 de abril de 2011

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report

scientific article published on 23 January 2020

Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion

artículo científico publicado en 2019

Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor

artículo científico publicado en 2005

Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma

artículo científico publicado en 2007

Prospects for therapeutic inhibition of neuroblastoma angiogenesis

artículo científico publicado en 2005

Proton versus photon radiation therapy for patients with high-risk neuroblastoma: the need for a customized approach

artículo científico publicado en 2013

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial

artículo científico publicado en 2013

Q&A: Crystal Mackall, John Maris on pediatrics

artículo científico publicado en 2013

QuantumClone: Clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction

artículo científico publicado en 2018

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma ⬇️

artículo científico publicado el 2 de febrero de 2011

Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)

artículo científico publicado en 2006

Rare MYC-amplified Neuroblastoma With Large Cell Histology.

artículo científico publicado en 2018

Rare copy number variants in over 100,000 European ancestry subjects reveal multiple disease associations

scientific article published on 14 January 2020

Rare variants in TP53 and susceptibility to neuroblastoma.

artículo científico publicado en 2014

Refining immunotherapeutic approaches to high-risk neuroblastoma based on tumor genomic profiles

artículo científico publicado en 2020

Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform

artículo científico publicado en 2005

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

artículo científico publicado en 2015

Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility

artículo científico publicado en 2012

Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans

artículo científico publicado en 2012

Reply to N.-K.V. Cheung et al

artículo científico publicado en 2014

Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19

artículo científico publicado en 2019

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting

artículo científico publicado en 2017

STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments

artículo científico publicado en 2006

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

artículo científico publicado en 2013

Safety and efficacy of tandem 131I‐metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma ⬇️

artículo científico publicado el 14 de abril de 2011

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

artículo científico publicado en 2012

Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group

artículo científico publicado en 2013

Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target

artículo científico publicado en 2010

Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma

artículo científico publicado en 2016

Significance of chromosome 1p loss of heterozygosity in neuroblastoma

artículo científico publicado en 1995

Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma

artículo científico publicado en 2020

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

artículo científico publicado en 2008

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

artículo científico publicado en 2010

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

artículo científico publicado en 2014

TB-16EXPLORATION OF eEF2K AS A NOVEL THERAPEUTIC TARGET IN MEDULLOBLASTOMA AND NEUROBLASTOMA.

artículo científico publicado en 2016

TBIO-29. PedcBioPortal, A CANCER DATA VISUALIZATION TOOL FOR INTEGRATIVE PEDIATRIC CANCER ANALYSES

artículo científico publicado en 2018

TM-06MYC AND MYCN DISRUPTION OF THE MOLECULAR CLOCK IN CANCER CELLS

TMOD-09. HUMAN PLURIPOTENT STEM CELL-BASED MODELS OF NEUROBLASTOMA

artículo científico publicado en 2017

Targeted Radiotherapy With Submyeloablative Doses of 131I-MIBG Is Effective for Disease Palliation in Highly Refractory Neuroblastoma ⬇️

artículo científico publicado el 1 de octubre de 2003

Targeting MYCN: a good BET for improving neuroblastoma therapy?

scientific article published on March 2013

Targeting PARP-1 with alpha-particles is potently cytotoxic to human neuroblastoma in pre-clinical models

scientific article published on 09 May 2019

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma

artículo científico publicado en 2016

Telomere maintenance mechanisms define clinical outcome in high-risk neuroblastoma

scientific article published on 14 April 2020

Testing of new agents in childhood cancer preclinical models: meeting summary

scientific article published on 01 December 2002

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

artículo científico publicado en 2011

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

artículo científico publicado en 2011

The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma

artículo científico publicado en 2006

The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease

artículo científico publicado en 2001

The challenge of defining "ultra-high-risk" neuroblastoma

scientific article published on 26 November 2018

The genetic landscape of high-risk neuroblastoma

artículo científico publicado en 2013

The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor

artículo científico publicado en 2008

The pediatric preclinical testing program: description of models and early testing results.

artículo científico publicado en 2007

The promises and pitfalls of genetic epidemiologic approaches to pediatric cancers: lessons from MDM2

artículo científico publicado en 2014

Thyroid and hepatic function after high‐dose 131I‐metaiodobenzylguanidine (131I‐MIBG) therapy for neuroblastoma ⬇️

artículo científico publicado el 9 de septiembre de 2010

Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).

artículo científico publicado en 2013

Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival

artículo científico publicado en 2012

Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

artículo científico publicado en 2017

Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome.

artículo científico publicado en 2015

Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma

artículo científico publicado en 2005

Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2.

artículo científico publicado en 2003

When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors

artículo científico publicado en 2019

YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

scientific article published on 31 October 2019

annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions

artículo científico publicado en 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda